Johnson & Johnson Signs Third Strategic Partnership with Changyida to Expand Neurovascular Intervention Portfolio into Microguidewires

Third collaboration: product line extends from flow diverters to access devices.

Third Contract Signing: Partnership Expands to Micro-guidewires

On September 1, Johnson & Johnson MedTech announced that the company had officially signed its third strategic cooperation agreement with Jiangsu CED Medtech Co., Ltd. The two parties will focus onNeurointerventional Microguidewire, collaborate on market expansion and technology promotion.

The division of labor between the two collaborating parties is clearly defined. Johnson & Johnson MedTech focuses on clinical insights, global resources, and commercialization capabilities, while Jiangsu CED Medtech provides local R&D and product translation capabilities. Christian Cuzick, Global Chairman of the Neurovascular Business at Johnson & Johnson MedTech, referred to the micro-guidewire as the “pioneer” in neurointerventional procedures, while Zhang Jiuli, General Manager of Jiangsu CED Medtech, summarized the signing as a further enhancement of the collaborative value between the two parties.

This marks the third contract signing between the two companies within three years. The scope of collaboration has gradually expanded from a single implantable product to neurointerventional access devices.

Time

Cooperation Progress

2023

Both Parties Sign Strategic Cooperation Agreement for the First Time

2025

Jointly Launching the Qiangyida Flow-Diverter Stent

Early 2026

Re-signing of the Upgraded Strategic Cooperation Agreement

September 2026

Third Contract Signing: Collaboration Scope Extended to Neurointerventional Microguidewires

This information boundary is critical. The Qiangyida dense-mesh stent has entered the public market phase, while the micro-guidewire remains in the product portfolio planning and business collaboration stage. The progress of these two products must not be conflated.

A micro guidewire to complete the access entry

Neurointerventional procedures involve small, tortuous, and densely branched intracranial vessels. A micro-guidewire first navigates through the target vessel to establish a pathway for the microcatheter, enabling subsequent stents, coils, thrombectomy devices, or other therapeutic instruments to reach the lesion site along this access route.

Micro-guidewires are extremely small in size, yet their performance requirements hinge on several interdependent parameters: the distal tip must be sufficiently soft to minimize the risk of vascular injury when navigating tortuous vessels; the proximal segment and shaft must provide pushability and support; torque transmission affects the operator’s control over the tip direction; while radiopacity, shape retention, coating smoothness, and guidewire–catheter compatibility influence the efficiency and stability of device delivery.

Basic Positioning of Neurointerventional Access

Catheter Sheath

Support Catheter

→

Distal Access Pathway

Catheter

→

Micro-guidewire

Microcatheter

→

Implantation or Treatment

Instruments

The schematic process is for understanding product positioning only; the specific device combination shall be subject to the registered scope of application and clinical selection.

Jiangsu CED Medtech Co., Ltd.’s currently available public product portfolio covers intracranial support catheters, distal access catheters, microcatheters, and introducer sheaths. According to its official website, registration certificates have been obtained for its intracranial support catheters, distal access catheters, microcatheters, and introducer sheaths.。

With the addition of micro guidewires, Jiangsu CED Medtech’s portfolio of access products will become more comprehensive. For clinical promotion, integrated product sets facilitate training, procedural communication, and product matching around a unified surgical workflow, thereby enabling the company to transition from single-product entry into hospital departments to covering multiple intraoperative stages.

Johnson & Johnson MedTech previously collaborated with Jiangsu CED Medtech on flow-diverting dense-mesh stents, which are implantable devices used in the treatment of intracranial aneurysms. The recent addition of micro-guidewires shifts the collaboration focus toward the anterior segment of surgical access pathways. While the unit price and market attention for micro-guidewires may be lower than those for dense-mesh stents, their clinical usage frequency, adaptability range, and departmental coverage value are more foundational.

Locally Developed, Integrated into the Global Commercial System

Since 2023, the two parties have adopted a phased approach to expanding their collaboration: first establishing a partnership, then launching the Qiangyida dense-mesh stent to the market, followed by upgrading the agreement and adding micro-guidewires. The pace has been relatively cautious, with each step centered on the advancement of specific products.

For Jiangsu CED Medtech, Johnson & Johnson MedTech’s neurointerventional team, clinical education expertise, and commercial channels help bring a new product into interventionalists’ view more quickly. Micro-guidewire usage habits are strongly influenced by operator preference, and new brands must undergo rigorous evaluation across multiple dimensions, including handling experience, catheter compatibility, navigability through complex vasculature, and batch-to-batch consistency. Market promotion cannot rely solely on obtaining a registration certificate.

For Johnson & Johnson MedTech, local partnerships can supplement its portfolio with products that are more closely aligned with China’s clinical needs and pricing environment. Combining a mature commercial platform with the R&D speed of domestic companies is a lighter and faster approach than building a product line from scratch. The addition of new products following the Qiangyida dense-mesh stent indicates that the previous phase of collaboration has laid a solid foundation for continued progress.

Registration Progress

Certificate Number and Scope of Application

Product Specifications

Diameter, Length, Tip

Cooperation Model

Brand and Commercial Rights

Clinical Implementation

Initial Use and Hospital Admission

The market for micro-guidewires has long seen competition between imported and domestically produced brands, with operators having developed clear preferences regarding tip feedback, support, and stability. For a new product to penetrate the market, obtaining regulatory approval is merely the first step. Only by gaining hospital access, ensuring compatibility with existing microcatheters, and delivering a consistent, reproducible procedural experience can it translate into sustained procurement.